Cumulative incidences of prostate cancer-specific mortality were @ % ( @ % CI @-@ ) in the STAS group , @ % ( @-@ ) in the STAS plus zoledronic acid group , @ % ( @-@ ) in the ITAS group , and @ % ( @-@ ) in the ITAS plus zoledronic acid group .